Application of theranostics in thyroid cancer management
The Journal of Clinical Endocrinology & Metabolism · 2026
DOI: 10.1210/clinem/dgag310 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Archana Sridhar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Metabolic Diseases Branch, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Theranostic Nanomedicine, Precision Medicine. Die Arbeit nennt 85 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), NIH.
Abstract (Originalsprache)
The incidental thyroid uptake of radiolabeled ligands used in positron emission tomography/computed tomography (PET/CT) targeting cell-surface proteins is observed in up to 6% of all scans. While diffuse thyroid uptake of ligands targeting somatostatin receptor type 2 (SSTR2), prostate-specific membrane antigen (PSMA), fibroblast activation protein (FAPI), or choline is observed in normal thyroid or usually signifies a benign thyroid abnormality, a heterogeneous or focal uptake is associated with malignant lesions in up to 19.7% of patients. The PET/CTs utilizing these ligands are characterized by decreased diagnostic sensitivity for detection of thyroid cancer metastases compared with cross-sectional imaging or 18-fluorodeoxyglucose PET/CT but are highly specific for detection of a subset of thyroid cancers characterized by a high target protein expression. Increased uptake of radiolabeled ligands targeting SSTR2, PSMA, FAPI, integrin αvβ3, and minigastrin can be used for patient selection for peptide receptor radionuclide therapy (PRRT). PRRT can be applied in clinical trials and/or off-label for patients with advanced radioactive iodine–refractory thyroid cancer who have limited treatment options or for medullary thyroid carcinoma of neuroendocrine origin. The PRRT-induced disease control rate approaches 60% and PRRT is well tolerated with limited side effects. Efficacy could be improved with careful patient selection based on the expression of molecular targets and their function, quantified by standard uptake values in diagnostic PET/CT imaging. Adopting an individualized dosimetry-based approach and synthesizing ligands with better tumor retention and residence time may help optimize treatment response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Metabolic Diseases Branch, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
ORCID-Profile: Joanna Klubo-Gwiezdzinska
Förderung
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- National Institutes of Health (NIH)
- NIH
- United States Government
- U.S. Department of Health and Human Services
Zitieren
APA
Sridhar, A., Behiri, N., & Klubo-Gwiezdzinska, J. (2026). Application of theranostics in thyroid cancer management. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgag310
Vancouver
Sridhar A, Behiri N, Klubo-Gwiezdzinska J. Application of theranostics in thyroid cancer management. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgag310
BibTeX
@article{Sridhar2026,
author = {Sridhar, Archana and Behiri, Noha and Klubo-Gwiezdzinska, Joanna},
title = {Application of theranostics in thyroid cancer management},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2026},
doi = {10.1210/clinem/dgag310}
}
EUVIMED